RQ Bio is a biotechnology company that develops medicine based on potent broad-spectrum mAbs to provide immunity to viral infections.
RQ Bio has raised $112.5M in total funding. The most recent round was Series A. The last funding was announced in June 2026.
RQ Bio's investors include Wellington Management, Oxford Science Enterprises, University of Oxford, Forbion Capital Partners, Frazier Life Sciences.
RQ Bio is headquartered in London, United Kingdom.
RQ Bio is a biotechnology company that develops medicine based on potent broad-spectrum mAbs to provide immunity to viral infections.
RQ Bio is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"RQ Bio — Funding & Investors." VCBacked, June 24, 2026, https://www.vcbacked.co/company/rq-bio. Accessed November 13, 2026.
VCBacked. (2026). RQ Bio — Funding & Investors. Retrieved November 13, 2026, from https://www.vcbacked.co/company/rq-bio
{{cite web |title=RQ Bio — Funding & Investors |url=https://www.vcbacked.co/company/rq-bio |website=VCBacked |access-date=November 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at RQ Bio? Request a listing update